Safety and efficacy of SARS‐Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR‐T cell infusion.

Patient N. 4 had moderate COVID-19 disease four months before cell therapy, requiring hospital admission and oxygen support because of interstitial pneumonia. Severe COVID-19 disease and COVID-19-related mortality were registered in 39% and 41% of patients, respectively. Starting from February 2021, the distribution of monoclonal antibody (MoA) casirivimab/imdevimab was authorized in Italy for the treatment of mild to moderate COVID-19 disease in patients at high risk for developing severe illness. COVID-19 infection has affected hematologic patients more severely than general population, probably due to underlying impaired immunity response, active chemotherapy and immunosuppressive treatment. [Extracted from the article]